BridgeMD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Plaque Psoriasis Involving Special Areas
EU CTIS ID: 2023-505122-34-00
What this study is testing
To evaluate the efficacy of JNJ-77242113 in participants with plaque psoriasis with at least moderate severity affecting special areas or lower BSA (range: ≥5% to <10%) moderate to severe plaque psoriasis.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. ≥12 years of age at the screening visit.
- 2. Diagnosis of plaque psoriasis, with or without PsA, for at least 26 weeks prior to the first administration of study intervention.
- 3. Candidate for phototherapy or systemic treatment for plaque psoriasis.
- 4. Need to meet criteria (a) and/or (b) a. Total BSA ≥1% at screening and baseline, AND IGA (overall) ≥2 at screening and baseline AND at least one of the following: - ss-IGA score ≥3 at screening and baseline, and/or - sPGA-G ≥3 at screening and baseline, and/or - hf-PGA score ≥3 at screening and baseline.
- 5. Failed to respond to at least 1 topical therapy used for treatment of psoriasis.
You likely can't join if
- 1. Nonplaque form of psoriasis.
- 2. Dermatoses other than plaque psoriasis or palmoplantar pustulosis of the palmoplantar area.
- 3. Current drug-induced psoriasis.
- 4. A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances.
- 5. Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients.
The study team makes the final eligibility decision.
Where it's taking place
- United Kingdom
- United States
- Canada
- Argentina
- Turkey
- Korea, Democratic People's Republic of
- Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United Kingdom; United States; Canada; Argentina; Turkey; Korea, Democratic People's Republic of and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.